Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Funding lifecycle and financial vocabulary

Seawolf launches with $100 million and Sanofi DNA research pact

Seawolf announced $100 million raised and a Sanofi DNA research pact with up to $1.2 billion in contingent milestones.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Seawolf Therapeutics announced a multi-target DNA medicines research collaboration and exclusive licence with Sanofi on November 16, 2026, alongside its public debut with $100 million raised. The San Diego company will pursue bleeding disorders and other unnamed indications with Sanofi, bringing a pharmaceutical partner into a research business whose lead programme remains at the animal-testing stage.

Sanofi partnership accompanies Seawolf’s public launch

The company’s November 16 announcement describes an agreement covering multiple targets, with Seawolf eligible for up to $1.2 billion in research, development and commercial milestones. It also provides for tiered royalties on sales of products resulting from the collaboration.

The agreement combines a research collaboration with an exclusive licence. That makes the announcement substantive for research operations: Seawolf is pairing development of its proprietary delivery platform with work directed toward a pharmaceutical partner’s programmes. The stated collaboration scope is bleeding disorders and additional unnamed indications.

BioSpace’s report separately identifies Seawolf’s lead programme as addressing metabolic diseases. Those two strands give the company an internal development programme alongside the newly disclosed partnership; the announcement describes them separately.

Financing raised and contingent licence payments

Fierce Biotech reports that the $100 million combines seed financing and a Series A. Versant Ventures led the seed round. The subsequent financing included Versant, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and others.

The investor group also includes Pathway to Cures, the philanthropic venture arm of the National Bleeding Disorders Foundation. Its participation places a disease-focused venture organisation among the company’s financial backers, alongside venture firms and drug developers.

Reuters reports that CEO Elizabeth Alcamo confirmed an upfront payment under the Sanofi agreement, with the amount undisclosed. The up-to-$1.2 billion figure concerns contingent milestones. It cannot be treated as cash already received or as a total committed research budget.

For readers comparing licence agreements, these are distinct economic categories: financing already raised, an undisclosed upfront payment, possible future milestones and royalties linked to resulting product sales. The conditions attached to a milestone payment matter when assessing how much of a headline transaction value can support research today.

A platform company built before its public debut

Seawolf began in 2021, Alcamo told Fierce Biotech. Its November 2026 emergence therefore follows several years of company development. In that interview, she described TRIDENT as combining a lipid nanoparticle, a proprietary DNA structure and an auxiliary component to support delivery into the cell nucleus.

The company’s technology description identifies three components: a DNA payload encoding a protein of interest, an mRNA payload encoding an auxiliary factor, and a targetable lipid nanoparticle formulation designed to carry DNA and RNA. This is Seawolf’s account of its research architecture.

Seawolf says its first applications involve expressing biologics from liver cells, with research underway to extend the platform to other organs and cellular targets. Its announcement describes proof-of-concept work in primates and mice. Reuters reports that the lead programme has been tested only in animals, placing the disclosed development work before human trials.

Seawolf’s leadership page names Alcamo as president and CEO and Rob Burke as chief scientific officer. It also identifies leaders for payload engineering, delivery technologies and development sciences. Those functions reflect the separate technical tasks involved in building a delivery system and advancing programmes based on it.

In the launch statement, Alcamo presented advancing the company’s metabolic-disease programme and collaborating with Sanofi as priorities for its next stage. BioPharma Dive’s coverage places both activities within the newly financed company’s plans. Versant managing director and Seawolf board chair Tom Woiwode also expressed support for the technology’s development in the announcement; that assessment comes from a founding investor.

What changes for research partners

For researchers and research offices following commercial translation, the concrete change is a newly public platform developer with venture financing and a multi-target pharmaceutical collaboration. The combination connects company-level capital with an agreement focused on selected disease areas, while retaining a separately described lead programme.

The operational distinction is between developing a platform and developing the individual programmes that use it. Seawolf’s technology page describes continuing delivery research beyond its first applications; the Sanofi agreement defines a collaboration around bleeding disorders and other indications. That distinction helps explain why the financing, licensing economics and scientific stage each require their own description.

Candidate selection and a trial filing are future steps

Reuters reports that Seawolf expects to select a drug candidate by late 2027 and file to begin human trials by the end of 2028. These are company expectations for the lead programme. Alcamo also told Reuters that additional capital would probably be needed to reach that stage.

The next development milestones therefore concern candidate selection and preparation for a human-trial filing. The November 16 collaboration adds a pharmaceutical research partner while the company continues the experimental and development work described at launch.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →